Nigeria Healthcare NSIA to Build Pharmaceutical Manufacturing Facility

Opportunities exist in Nigeria for U.S. suppliers of laboratory and pharmaceutical equipment due to plans by the Nigeria Sovereign Investment Authority (NSIA) to set to up a manufacturing facility to produce active pharmaceutical ingredients (API), excipients, and vaccines for domestic supply and export to the West African region. The NSIA, an investment institution managing the country’s excess hydrocarbon revenues, has already commissioned a detailed feasibility study on the project and results are expected soon. The total project cost, including equipment, will be determined after the study. According to NSIA sources, bids for pharmaceutical and laboratory equipment supply will be published after the organization’s management and board completes review of the feasibility report.

NSIA’s mission is to play a leading role in driving sustained economic development for the benefit of all Nigerians through building a savings base for the Nigerian people, enhancing the development of Nigeria’s infrastructure, and providing stabilization in times of economic stress. NSIA is currently managing over $3 billion of investment projects in Nigeria. Through its healthcare investment vehicle, NSIA Healthcare Development and Investment Company (NHDIC), the organization has signed memorandum of cooperation with the Federal Ministry of Health and six federal medical centers and teaching hospitals across the country’s six geopolitical zones. The development will provide diagnostic centers and specialist healthcare facilities co-located within the federal healthcare institutions.

For follow up and more information on this market intelligence report, please contact Chamberlain Eke, Commercial Specialist, Email: Chamberlain.eke@trade.gov